Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Metabolon Announces Findings from Two Major Diabetes Outcomes Studies

Published: Tuesday, June 25, 2013
Last Updated: Monday, July 08, 2013
Bookmark and Share
This provides further evidence that the Quantose test identifies individuals at risk for type 2 diabetes earlier and more accurately than traditional risk factors alone.

Metabolon, Inc. announces results from two large-cohort studies evaluating the clinical utility of Quantose, the company’s blood test for prediabetes. 

The performance of Quantose was measured among 3,841 participants from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) and Botnia Prospective Study cohorts. Notably, among initially healthy participants in the RISC study with 3-year follow-up data:

Quantose biomarkers α-hydroxybutyrate (α-HB) and linoleoyl-glycerophosphocholine (L-GPC) independently and significantly predicted worsening glycemic control, and;

Quantose outperformed traditional risk measures such as fasting insulin, fasting glucose, BMI, and HOMA-IR in predicting insulin resistance and progression to impaired glucose tolerance.

In the Botnia Prospective Study with 9.5 year follow-up data:

Quantose biomarkers were found to predict incident type 2 diabetes independent of familial diabetes, sex, age, BMI, and fasting glucose.

These findings were published in two recent articles:

“Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance”,Diabetes; Ferrannini, Gall,; 2013; 62(5): 1730.

“A Novel Fasting Blood Test for Insulin Resistance and Prediabetes” Journal of Diabetes Science and Technology; Ferrannini, Cobb,; 2013; 7(1): 100.

The Quantose test reflects insulin resistance and detects progression to prediabetes and diabetes earlier than traditional glycemic measures such a hemoglobin A1C. The test is particularly useful in identifying prediabetic patients at greatest risk of disease progression and for whom drug, or other interventional therapy, may be appropriate. Diagnostic assessment with the Quantose test is well-aligned with the American Diabetes Association guidelines which recommend that physicians consider pharmaceutical intervention in high-risk prediabetics.

Beyond its immediate impact on the treatment of prediabetes, Quantose offers convincing evidence of the maturation of the field of metabolomics -- and of the potential influence the discovery of novel metabolomic biomarkers will have on personalized medicine. Metabolon is committed to utilizing its systematic metabolomics discovery approach to develop diagnostics in the areas of metabolic, cancer and cardiovascular disease and provide biomarker research services by employing their high-throughput, advanced metabolomics platform.

“These studies are clear affirmation of Quantose value to predict early those individuals at risk for eventual onset of Type 2 diabetes which may provide clinicians the opportunity for treatment interventions that may reverse the prediabetic state,” Eric Button, Senior Vice President of Diagnostics, Metabolon commented.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Study Shows Quantose IR™ Measures Insulin Sensitivity Better
Results were recently published online by the Journal of Clinical Endocrinology & Metabolism.
Wednesday, April 01, 2015
Metabolon, Baylor Partner to Screen for Inborn Errors of Metabolism
The two-year, exclusive agreement will provide global Metabolomic-Assisted Pathway Screening (MAPS) services for individuals with suspected inborn errors of metabolism (IEMs).
Thursday, September 04, 2014
Metabolon, Geisinger Partner on Prediabetes Study
Metabolon will sponsor a pilot study to evaluate its Quantose IRTM test as a monitor of glycemic control in people with prediabetes.
Friday, June 27, 2014
New Study Reveals Interplay between Genetics and Metabolism in Complex Disease
Metabolomic profiling coupled with genomics data yields new insight into diseases, potential biomarkers and drug treatments.
Saturday, May 17, 2014
Interplay between Genetics and Metabolism in Complex Disease Revealed
Metabolomic profiling coupled with genomics data yields new insight into diseases, potential biomarkers and drug treatments
Friday, May 16, 2014
Metabolon Enters into Collaboration with GSK
Agreement will see Metabolon provide metabolomic profiling services to GlaxoSmithKline.
Wednesday, May 14, 2014
Metabolon Debuts New Client Portal at Bio-IT World Expo
MetaboLync™ is a cloud-based solution for sharing, visualizing, and analyzing metabolomics data.
Wednesday, April 30, 2014
Microbes and Metabolites Fuel an Ambitious Aging Project
Craig Venter’s new company wants to improve human longevity by creating the world’s largest, most comprehensive database of genetic and physiological information.
Wednesday, March 12, 2014
Collaboration Agreement to provide Metabolomic Profiling Services
Metabolon Inc will assist Human Longevity Inc to build the world’s largest and most complete human genotype, microbiome and phenotype database.
Wednesday, March 05, 2014
Metabolon Closes $15 Million Series E Financing
Company raises $15 million through the issuance of preferred stock.
Monday, January 06, 2014
Global Genomics Group and Metabolon to Collaborate
Metabolon will conduct biochemical profiling in single largest prospective pan-omic study.
Thursday, November 14, 2013
Metabolon and Bostwick Laboratories Announce Marketing Agreement
Under the Agreement Bostwick will market Prostarix™, a non-invasive urine test for stratifying prostate cancer risk.
Monday, November 04, 2013
Impaired Metabolism in Cystic Fibrosis Lung Epithelial Cells Revealed by Metabolic Analysis
Metabolon announces publication of “Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis Cells”.
Monday, October 25, 2010
Metabolon Awarded US Patent for Metabolic Biomarkers of Efficacy of PPAR Affecting Drugs
The USPTO awarded the patent to Metabolon on October 5, 2010.
Thursday, October 21, 2010
Metabolon Extends Biochemical Understanding of Alzheimers Disease
Publishes “Ablation of the Locus Coeruleus Increases Oxidative Stress in Tg-2576 Transgenic But Not Wild-type Mice” in the International Journal of Alzheimer Disease.
Thursday, October 14, 2010
Scientific News
Newly Identified Biochemical Pathway Could Be Target for Insulin Control
Researchers at Duke Medicine and the University of Alberta are reporting the identification of a new biochemical pathway to control insulin secretion from islet beta cells in the pancreas, establishing a potential target for insulin control.
Dirty,Crusty Meals Fit for (Long-Dormant) Microbes
Researchers apply the latest analytical techniques to further our understanding of desert biocrusts.
CSI -- On The Metabolite's Trail
Bioinformaticians at the University of Jena make the most efficient search engine for molecular structures available online.
Developing a Breathalyzer-Type Low Blood Sugar Warning Device For Diabetes
A multidisciplinary team of researchers at Indiana University-Purdue University Indianapolis has been awarded a $738,000 National Science Foundation grant to develop a breathalyzer-type device to detect the onset of hypoglycemia, or low blood sugar episodes, in people with diabetes.
Identifying The 'Dimmer Switch' Of Diabetes
University of Alberta research gives new insight into what causes Type 2 diabetes.
10 to 1: Bugs Win in NASA study
Bugs are winning out, and that's a good thing according to NASA's Human Research Program.
MYC Oncogene Disrupts Cancers Rhythm
Findings inform time-dependent treatment for reducing side effects and increasing effectiveness of cancer medications.
Keeping Gut Bacteria in Balance Could Help Delay Age-related Diseases
A new study suggests that analyzing intestinal bacteria could be a promising way to predict health outcomes as we age.
Genome Mining Effort Discovers 19 New Natural Products in Four Years
Each of these products is a potential new drug. One of them has already been identified as an antibiotic.
New CRISPR-Cas9 Strategy Edits Genes Two Ways
A team of Harvard and MIT researchers have developed a way to perform genome engineering and gene regulation at the same time.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos